Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies
NCT04283006Phase 1Recruiting
- Start
- May 2018
- Primary completion
- May 2023
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD20/CD22 dual targeted CAR T-cells in acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 3 more. Primary endpoints: Dose-limiting toxicity at 28 days and Treatment-emergent adverse events at 2 years. Started May 2018; status: recruiting.
02
Drugs
CD20/CD22 dual targeted CAR T-cells
03
Conditions
acute lymphoblastic leukemia (ALL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)primary mediastinal large B-cell lymphoma (PMBCL)high grade B-cell lymphoma (HGBCL)
Beyond the preview
Go deeper on NCT04283006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04283006.